Views:
3,307
Published:
19 y
Re: Aids Cure??
http://v3.espacenet.com/textdoc?DB=EPODOC&IDX=EA4203&F=8
ANTIVIRAL AND ANTIBACTERIAL PHARMACEUTICAL PREPARATION "ARMENICUM" AND THE USE THEREOF FOR TREATMENT OF INFECTIOUS DISEASES
Publication number:EA4203 Publication date:2004-02-26 Inventor:ILYIN ALEXANDER (KZ); GABRIELYAN EMIL (AM); MKHITARYAN LEVON (AM) Applicant:ARMENICUM & JSC (AM) Classification: - international:A61K31/70; A61K33/14; A61K33/18; A61P31/04; A61P31/12; A61K31/70; A61K33/14; A61K33/18; A61P31/00; (IPC1-7): A61K33/18; A61K31/70; A61K33/14; A61P31/04; A61P31/12; A61K31/14; A61K33/18 - european: Application number:EA20020001039 20001124 Priority number(s):AM20000000032 20000417; WO2000AM00002 20001124
Abstract of EA4203
1. Antiviral and antibacterial pharmaceutical preparation containing iodine, potassium or sodium iodide, sodium chloride, lithium chloride, synthetic water-soluble polymer, mono-, oligo- and polysaccharides and water, characterized in that it additionally contains halogenderivatives of natural compounds in the following proportion of ingredients, g/1:
Iodine 0.8-25 Potassium or sodium
Iodide 1.2-38 Sodium chloride 9 Lithium chloride 0.1-20 Synthetic water-soluble polymer 0.01-6 Mixture of mono-, oligo- and polysaccharides 8-400 Mixture of halogenderivatives of natural 0.001-0.01 Water the rest 2. The pharmaceutical preparation according to Claim 1, characterized in that halogenderivatives of mono-, oligo- and polysaccharides are used as halogenderivatives of natural compounds. 3. The use of pharmaceutical preparation according to Claims 1 or 2 in treatment of mammals, including humans, infected with viral and bacterial infections. 4. The use of pharmaceutical preparation according to Claim 3, characterized in that pharmaceutically effective amount of the preparation is administered intravenously. 5. The use of pharmaceutical preparation according to Claim 4, characterized in that the preparation is preliminarily diluted with physiological solution of sodium chloride from 1:4 to 1:30 volume ratio. 6. The use of pharmaceutical preparation according to Claims 4-5, characterized in that the preparation is administered at a speed of 4-9ml/min. 7. The use of pharmaceutical preparation according to Claim 3 characterized in t h a t pharmaceutically effective amount of the preparation is administered intramuscularly, intraperitoneally, subcutaneously or orally. 8. The use of pharmaceutical preparation according to any of Claims 3-7 characterized in that the preparation is applied for HIV-infection treatment. 9. The use of pharmaceutical preparation according to any of Claims 3-7 characterized in that the preparation is used for treatment of AIDS and associated opportunistic diseases.